Purple Biotech (PPBT) AI Stock Analysis

• Market Cap: $6.00M
• Dividend Yield: N/A
• Average Volume (3M): 415.61K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.68
• Revenue Growth: N/A
• EPS Growth: 88.64%
• Country: US
• Employees: 9
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -19.85
• Shares Outstanding: 929,240
• 10 Day Avg. Volume: 296,099
• 30 Day Avg. Volume: 415,608
• PEG Ratio: >-0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: -1.12
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 44.53
• Enterprise Value/Ebitda: 0.26
• 1Y Price Target: $30.00
• Price Target Upside: 651.88% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -19.3
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $4.00 ▲(0.25% Upside)
• Action: Reiterated Date: 03/16/26
• Date: Action: Reiterated 03/16/26

The score is held down primarily by weak financial performance (minimal revenue, widening losses, and continued cash burn alongside a shrinking equity base). Technicals are also bearish with negative momentum and price below key moving averages, only partially offset by oversold signals. Valuation contributes little support due to unprofitability and no dividend data.

Positive Factors

Strong Partnerships

Partnerships and collaborations provide a sustainable revenue stream through upfront payments, milestone payments, and potential royalties, enhancing financial stability and growth prospects.

Low Leverage

Low leverage reduces financial risk and enhances the company's ability to navigate economic downturns, providing a stable foundation for future growth.

Clinical Progress

Advancements in clinical milestones and pipeline progress indicate potential for future product launches, which can drive long-term revenue growth and market expansion.

Negative Factors

Consistent Net Losses

Ongoing net losses highlight financial instability, limiting the company's ability to invest in growth opportunities and potentially affecting long-term viability.

Negative Cash Flow

Negative cash flow reflects inefficiencies in cash generation, necessitating reliance on external financing, which could constrain future operational flexibility and growth.

Revenue Challenges

The absence of revenue growth underscores significant operational challenges, limiting the company's ability to achieve profitability and sustain long-term operations.

Purple Biotech Business Overview & Revenue Model

Company Description

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

How the Company Makes Money

Purple Biotech primarily generates revenue through business development transactions tied to its drug candidates—such as licensing agreements, collaboration arrangements, and similar partnerships that can include upfront payments, development/regulatory milestone payments, and royalties on future product sales if partners successfully commercialize partnered assets. The company may also record other income items related to such arrangements (e.g., reimbursement of certain development activities) when applicable. Product-sales revenue is generally not a core driver unless a product is commercialized by the company or it receives royalty/participation revenue via a partner; specific counterparties, deal terms, and the current contribution of each stream to earnings are null.

Purple Biotech Financial Statement Overview

Summary

Financials are constrained by persistent losses, minimal revenue, and ongoing cash burn. Leverage is low, but the sharp decline in equity materially reduces the financial cushion and increases reliance on future financing.

Income Statement

Operating performance remains very weak, with persistent losses across the period and a sharp deterioration in 2025 (annual) as net loss widened to about $26.8M vs. $7.2M in 2024. Revenue is effectively nonexistent in most years (including 2024–2025), highlighting an early-/pre-commercial profile and limited ability to offset operating costs. While low revenue can be normal for biotech, the scale and volatility of losses points to elevated earnings risk and ongoing dependence on external funding.

Balance Sheet

Leverage is low, with total debt modest and debt-to-equity staying very small (roughly 0.6%–2.5% across the period), which limits balance-sheet financial risk. However, the equity base has fallen sharply (from ~$79.4M in 2020 to ~$9.7M in 2025), reflecting cumulative losses and meaningfully reduced financial cushion. Returns on equity are negative, underscoring value dilution risk if losses continue and additional capital is required.

Cash Flow

Cash generation is consistently negative, with operating cash flow and free cash flow both deeply in the red each year, indicating ongoing cash burn. Cash burn improved in 2024 versus 2023, but reversed in 2025 with free cash flow worsening to about -$5.5M. Free cash flow is roughly in line with net losses (around 1x in most years), suggesting losses are translating into real cash outflows rather than being primarily accounting-driven.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	195.80K	0.00	0.00
Gross Profit	0.00	-186.00K	-196.00	-120.00	-55.00
EBITDA	-27.68M	-7.05M	-19.88M	-21.49M	-17.52M
Net Income	-26.81M	-7.24M	-19.88K	-21.67M	-18.38M
Balance Sheet
Total Assets	17.57M	37.04M	44.30M	54.62M	70.20M
Cash, Cash Equivalents and Short-Term Investments	9.57M	8.52M	15.41M	32.11M	47.20M
Total Debt	244.00K	183.00K	351.00K	515.00K	749.00K
Total Liabilities	7.91M	4.13M	10.01M	7.52M	5.09M
Stockholders Equity	9.71M	32.86M	34.21M	46.91M	64.83M
Cash Flow
Free Cash Flow	-5.54M	-14.37M	-19.93M	-16.96M	-15.19M
Operating Cash Flow	-5.54M	-14.37M	-19.93M	-16.73M	-15.07M
Investing Cash Flow	449.54K	509.00K	13.88M	19.91M	13.41M
Financing Cash Flow	6.41M	6.77M	5.45M	1.11M	1.51M

Purple Biotech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.99
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PPBT, the sentiment is Negative. The current price of 3.99 is below the 20-day moving average (MA) of 4.76, below the 50-day MA of 5.72, and below the 200-day MA of 12.22, indicating a bearish trend. The MACD of -0.50 indicates Positive momentum. The RSI at 34.26 is Neutral, neither overbought nor oversold. The STOCH value of 18.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PPBT.

Purple Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TCRT	45 Neutral	$6.96M	-1.13	-167.97%	―	―	68.59%
PPBT	42 Neutral	$6.00M	―	-10.00%	―	―	88.64%
KALA	40 Underperform	$229.75M	-0.36	-2323.94%	―	―	52.39%
OGEN	29 Underperform	$3.36M	―	-168.95%	―	―	90.27%

Purple Biotech Corporate Events

Purple Biotech Posts 2025 Loss, Doubles Down on CAPTN-3 Immunotherapy Platform

On March 13, 2026, Israel-based Purple Biotech reported fourth-quarter and full-year 2025 results that underscored a strategic pivot toward its CAPTN-3 tri-specific antibody platform, advancing lead candidate IM1240 and naming IM1305 as a second development candidate. The company highlighted positive preclinical data, toxicology results showing an expanded therapeutic window for IM1240, and achievement of commercially viable manufacturing yields, while disclosing that legacy assets CM24 and NT219 have been impaired and will only progress with external funding or partners.

For the fourth quarter of 2025, Purple Biotech’s research and development and general and administrative expenses rose sharply, and a $20.5 million non-cash impairment on CM24 and NT219 drove a net loss of $23.6 million. For the full year 2025, net loss widened to $26.4 million despite lower clinical trial spending, but with cash and equivalents of $9.5 million at year-end and an expected runway into 2027, the company signaled it is financially positioned to push CAPTN-3 toward a planned Phase 1 trial of IM1240, reinforcing its focus on high-potential T cell engager and masked antibody modalities in oncology.

The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.

Purple Biotech to Implement ADS Ratio Change to Regain Nasdaq Bid-Price Compliance

On February 25, 2026, Purple Biotech announced it will change the ratio of its American Depositary Shares to ordinary shares from 1:200 to 1:2,000, effectively a one-for-ten reverse ADS split. The revised ADSs are expected to begin trading on or about March 2, 2026, on Nasdaq under the existing ticker PPBT but with a new CUSIP, while the company’s Tel Aviv–listed ordinary shares remain unaffected by the move.

The primary goal of the ADS ratio change is to lift the ADS trading price to help Purple Biotech regain compliance with Nasdaq’s $1.00 minimum bid requirement and improve the suitability of its securities for continued trading. Fractional ADS entitlements will be aggregated and sold for cash by the depositary, and the company expects the ADS price to rise proportionally, though it cautions there is no assurance the increase will match the tenfold ratio adjustment.

The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.

Purple Biotech Unveils January 2026 Corporate Update, Mapping 2026 Catalysts for CAPTN-3 and Oncology Pipeline

On January 12, 2026, Purple Biotech released an updated corporate presentation outlining progress on its CAPTN‑3 tri‑specific antibody platform and near‑term milestones for its oncology pipeline. The company highlighted lead candidate IM1240, a capped CD3x5T4xNKG2A antibody for solid tumors that showed a 300‑fold safety margin versus its non‑capped variant in preclinical models and is slated for GLP toxicology completion, IND submission, and Phase 1 initiation in the second half of 2026. The presentation also positioned Phase 2 assets CM24 (pancreatic cancer) and NT219 (head and neck cancer) as partnership opportunities, with interim Phase 2 data for NT219 expected in 2026 and a Phase 2b start for CM24 contingent on partnering, framing 2026 as a catalyst‑rich year that could de‑risk the CAPTN‑3 platform and potentially enhance Purple Biotech’s standing in the competitive immuno‑oncology space.

The most recent analyst rating on (PPBT) stock is a Hold with a $0.66 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.

Purple Biotech Reports Key Toxicology Milestone for CAPTN-3 Antibody IM1240

On January 7, 2026, Purple Biotech reported that its tri-specific antibody IM1240, from the CAPTN-3 platform, successfully completed a non-human primate toxicology study, showing dosing tolerance up to 300 times higher than a non-capped comparator with markedly reduced immune-related toxicity and minimal cytokine release. The study also demonstrated a favorable pharmacokinetic profile, including increased systemic exposure and prolonged half-life attributed to IM1240’s capping design and albumin moiety, reinforcing the potential for an expanded therapeutic window and supporting its progression toward first-in-human clinical development with further advanced toxicological assessments planned.

The most recent analyst rating on (PPBT) stock is a Hold with a $0.65 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.

Purple Biotech Shareholders Approve Key Proposals at December Meeting

On December 15, 2025, Purple Biotech Ltd. held an Extraordinary General Meeting of Shareholders at its headquarters in Rehovot, Israel. During the meeting, all proposals outlined in the company’s Proxy Statement were approved by the shareholders, in accordance with Israeli Companies Law and the company’s articles of association. This approval signifies a strategic alignment among stakeholders, potentially impacting the company’s future operations and market positioning.

The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.